×
About 35,320 results

Continuous Erector Spinae Block for Post Analgesia in Pediatric Patients
https://clinicaltrials.gov/ct2/show/NCT04613830

Feb 3rd, 2023 - Sixty patients will be included in this prospective randomized study. The patients will be allocated into two groups: the ESPB group (group E, n = 30) and the tramal group (group T, n =30). All patients will receive standard general anesthesia. Ultrasound-guided ESPB will be performed to group erector spinae plane block

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
https://clinicaltrials.gov/ct2/show/NCT04041050

Feb 3rd, 2023 - There are 5 parts to this study for which the primary objectives are to evaluate safety, tolerability, and pharmacokinetics (PK) of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have been receiving a stable dose of ruxolitinib therapy for at least 12 weeks prior to study enrollment. In Part 3, all eligible...

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
https://clinicaltrials.gov/ct2/show/NCT02471144

Feb 3rd, 2023 - The purpose of this study was to demonstrate superior efficacy of secukinumab versus placebo at Week 12, based on both PASI 75 and IGA mod 2011 0 or 1 response rates in children and adolescents aged 6 to less than 18 years with severe chronic plaque psoriasis who had inadequate control of symptoms with topical treatment, or failed to respond to or tolerate previous systemic treatment and/or UV ...

Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT02583893

Feb 3rd, 2023 - PRIMARY OBJECTIVES: I. To test the association between biochemical response and clinical response. SECONDARY OBJECTIVES: I. To estimate complete response rate of sirolimus MEC in patients with high risk AML. II. To estimate progression free survival in this patient population. III. To collect further information on the safety, tolerability, and efficacy of sirolimus in combination with MEC in p...

Galcanezumab for Vestibular Migraine
https://clinicaltrials.gov/ct2/show/NCT04417361

Feb 3rd, 2023 - Vestibular migraine (VM) is a distinct subtype of migraine that causes episodic vertigo/dizziness, sometimes with headache, and sometimes without. However, unlike traditional migraines, patients generally seek out care because of dizziness, and not because of headache. Therefore, these patients are cared for by a variety of providers who treat dizziness, including otolaryngologists and neurolog...

Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery
https://clinicaltrials.gov/ct2/show/NCT02797548

Feb 3rd, 2023 - Subjects who can not be randomized due to any reason will be enrolled at observational group.

Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis
https://clinicaltrials.gov/ct2/show/NCT03912428

Feb 3rd, 2023 - I. Objective 18-kDa translocator protein (TSPO) and cyclooxygenase-2 (COX-2) are both implicated in the pathophysiology of various inflammatory disorders, suggesting that both may serve as potential biomarkers of inflammation in brain as well as periphery. Our laboratory recently developed two new radioligands: [11C]ER176 to image TSPO and [11C]MC1 to image COX-2. Using wholebody imaging, this ...

Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0)
https://clinicaltrials.gov/ct2/show/NCT04198428

Feb 3rd, 2023 - The proposed study will include 3 large diverse healthcare systems and randomize a minimum of 30 clinics equally within each system to receive the OUD-CDS intervention or UC. In intervention and UC clinics, the OUD-CDS will identify study-eligible patients, those who are at high risk for OUD or diagnosed with OUD; and will use data stored in the EHR to assemble treatment recommendations tailore...

A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT04188119

Feb 3rd, 2023 - TNBC is an aggressive subtype of breast cancer associated with poor survival and new treatments are needed. A key feature of cancer is its ability to go undetected by the immune system. Recent developments in cancer research have identified immune checkpoints as a possible treatment option as they seem to promote an anti-tumour immune response. Some breast cancers have considerable cancer cell ...

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
https://clinicaltrials.gov/ct2/show/NCT04995029

Feb 3rd, 2023 - This study consists of an open-label induction phase followed by a double-blind maintenance phase. Each phase is designed to test separate objectives and endpoints. In the induction phase participants who use opioids via an injection route and/or use high doses of opioids who are in withdrawal will be randomly assigned in a 2:1 ratio to extended-release buprenorphine rapid induction or SoC indu...

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
https://clinicaltrials.gov/ct2/show/NCT04580121

Feb 3rd, 2023 - The study will include AML participants with measurable disease, for whom standard-of-care (SOC) is not available. Two Groups of AML participants will be included in this study: Group I participants will have hematologic relapse/refractory disease defined as participants not in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi). Group II participants will h...

Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
https://clinicaltrials.gov/ct2/show/NCT05174065

Feb 3rd, 2023 - The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).

Nitrous Oxide for Analgesia During Nasogastric Tube Placement in Young Children
https://clinicaltrials.gov/ct2/show/NCT04008628

Feb 3rd, 2023 - In the context of mild to moderate dehydration in young children, enteral rehydration is the treatment of choice because it is more physiological than parenteral rehydration which has more serious side effects. Thus, nasogastric tube placement has become a more common procedure in the pediatric emergency care setting. Although, it is widely accepted that this procedure is invasive and painful, ...

Dexmedetomidine-Ropivacine Versus Sufentanil-Ropivacaine for Epidural Labor Analgesia
https://clinicaltrials.gov/ct2/show/NCT05698407

Feb 3rd, 2023 - Sufentanil combined with ropivacaine is commonly used for epidural labor anesthesia. However, this combination is associated with some adverse events including increased risk of neonatal depression. Dexmedetomidine is a high selective alpha2-adrenoceptor agonist and possesses opioid-sparing and analgesic effects when used in combination with local anesthetics. Recently published data suggest th...

Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department
https://clinicaltrials.gov/ct2/show/NCT05325580

Feb 3rd, 2023 - Rate of Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department

Perioperative Methadone in Hip Fracture Patients
https://clinicaltrials.gov/ct2/show/NCT05581901

Feb 3rd, 2023 - A multimodal approach and the use of peripheral nerve blocks have improved the treatment of postoperative pain. However, supplemental opioids are predominantly necessary and often continued for months or years after surgery. In fact, continued use of opioids after surgery is an increasing challenge. Consequently, patients undergoing surgery are at risk of experiencing side effects and developin...

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
https://clinicaltrials.gov/ct2/show/NCT05587998

Feb 3rd, 2023 - This is a Phase 1, single-centre, randomized, double-blind, placebo-controlled, 2 fixed sequences, multiple dose study in healthy male and/or female recreational opioid users. This study is being primarily conducted to assess the effect on respiratory drive of morphine administered after multiple doses of AZD4041 compared to morphine administered alone in healthy recreational opioid users. The ...

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
https://clinicaltrials.gov/ct2/show/NCT05597878

Feb 3rd, 2023 - Primary Objective(s): Compare the effectiveness of opioid and opioid-free pathways in treating post-surgical pain following robotic-assisted radical prostatectomy. Secondary Objective(s) To determine the opioid usage in the opioid and non-opioid group from the start of the pain treatment administration until discharge in patients following robotic-assisted radical prostatectomy. Determine and a...

Open Label Comparison of Injectable Buprenorphine ( Brixadi®) and Naltrexone (Vivitrol®) for Opioid Use Disorder
https://clinicaltrials.gov/ct2/show/NCT05596955

Feb 3rd, 2023 - This study will elucidate the cognitive mechanisms of response to opioid agonists and antagonists used to prevent relapse in OUD through investigation of the underlying neural circuits. The study will use previously validated cognitive probes, functional Magnetic Resonance Imaging (fMRI), and extended-release injectable preparations of opioid partial agonist buprenorphine (XRBUP, Brixadi) and o...

Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling
https://clinicaltrials.gov/ct2/show/NCT05257824

Feb 3rd, 2023 - The purpose of this study is to compare the incidence of thromboembolic and hemorrhagic complications between 1 and 18 months after stent-assisted coiling according to the duration of use of dual antiplatelet agents (6 months versus 12 months) after stent-assisted coiling of unruptured intracranial aneurysms to determine the optimal duration of use of dual antiplatelet agents.